Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in high-risk pregnant women with early onset severe HDFN
2017-004958-42Phase 2Unknown
- Sponsor
- Momenta Pharmaceuticals
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nipocalimab in Erythroblastosis fetalis (HDFN) and Rhesus hemolytic disease, sponsored by Momenta Pharmaceuticals. Primary endpoint: Incidence and severity of adverse events. Status: unknown.
02
Drugs
nipocalimab
03
Conditions
Erythroblastosis fetalis (HDFN)Rhesus hemolytic disease
Beyond the preview
Go deeper on 2017-004958-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004958-42.